Skip to content

The investigation of the pathological morphology, genomic characteristics, and drug sensitivity of sarcoma with definite molecular signatures

The investigation of the pathological morphology, genomic characteristics, and drug sensitivity of sarcoma with definite molecular signatures

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500098518
Enrollment
Unknown
Registered
2025-03-10
Start date
2025-04-10
Completion date
Unknown
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcoma

Interventions

Sarcoma with definite molecular signatures patients group:None
Sarcoma without definite molecular signatures patients group:None

Sponsors

Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-75 years old, male or female; 2. Patients diagnosed with sarcoma through histopathological examination at our hospital since 2020; 3. Patients with definitive molecular signatures, including inactivation of tumor suppressor genes, gene fusion/genomic rearrangement, and copy number variations confirmed by NGS or FISH; patients with suggestive molecular abnormalities (such as IHC demonstrating abnormal expression of relevant proteins); and patients exhibiting corresponding histopathological subtypes but lacking definitive molecular signatures. 4. Patients with adequate pre-treatment tissue specimens available for study (within 5 years; For needle biopsy specimens, about 20 slides or cutting rolls with a thickness of 5-10µm were used. For surgical specimens, about 10 slides or cutting rolls with a thickness of 5-10µm were used. The sections were placed on anti-detachment glass slides or the cutting rolls were placed in EP tubes. Be careful not to collect strong acid decalcified bone tissue samples. Pay attention to disinfect the microtome and the table, and replace different samples with new blades to prevent cross contamination.)

Exclusion criteria

Exclusion criteria: 1. Patients lacking detailed histopathological diagnostic reports and routine clinical follow-up data; 2. Patients with inadequate tissue samples for testing, or those who have only limited biopsy specimens; 3. Patients whose tissue samples fail to pass the quality control;

Design outcomes

Primary

MeasureTime frame
Inactivation of tumor suppressor genes;Gene fusion or genomic rearrangement;Copy number variation;

Countries

China

Contacts

Public ContactZebing Liu

Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine

18719@renji.com+86 21 68383349

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026